JBM (Healthcare) Signs 2025 Europharm License Agreement

Reuters10-28

JBM (Healthcare) Signs 2025 Europharm License Agreement

JBM (Healthcare) Ltd. has announced that Europharm and Europharm HK have entered into the 2025 Europharm License Agreement on 28 October 2025. Under this agreement, Europharm will grant a license to Europharm HK to use a portion of the Factory from 1 December 2025 to 27 January 2028, for a monthly license fee of HK$247,000. The agreement follows the expiration of the previous license on 30 November 2025. The directors of both Jacobson and JBM, including their independent non-executive directors, consider the terms of the agreement to be fair, reasonable, on normal commercial terms, and in the best interests of the companies and their shareholders. Certain directors abstained from voting on the relevant board resolutions to avoid potential conflicts of interest.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JBM (Healthcare) Ltd. published the original content used to generate this news brief on October 28, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2578932037?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-28 18:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578932037","market":"us","top_or_hot":-1,"title":"JBM (Healthcare) Signs 2025 Europharm License Agreement","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      JBM (Healthcare) Signs 2025 Europharm License Agreement\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        JBM (Healthcare) Ltd. has announced that Europharm and Europharm HK have entered into the 2025 Europharm License Agreement on 28 October 2025. Under this agreement, Europharm will grant a license to Europharm HK to use a portion of the Factory from 1 December 2025 to 27 January 2028, for a monthly license fee of HK$247,000. The agreement follows the expiration of the previous license on 30 November 2025. The directors of both Jacobson and JBM, including their independent non-executive directors, consider the terms of the agreement to be fair, reasonable, on normal commercial terms, and in the best interests of the companies and their shareholders. Certain directors abstained from voting on the relevant board resolutions to avoid potential conflicts of interest.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JBM (Healthcare) Ltd. published the original content used to generate this news brief on October 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JBM (Healthcare) Signs 2025 Europharm License Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJBM (Healthcare) Signs 2025 Europharm License Agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-28 18:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      JBM (Healthcare) Signs 2025 Europharm License Agreement\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        JBM (Healthcare) Ltd. has announced that Europharm and Europharm HK have entered into the 2025 Europharm License Agreement on 28 October 2025. Under this agreement, Europharm will grant a license to Europharm HK to use a portion of the Factory from 1 December 2025 to 27 January 2028, for a monthly license fee of HK$247,000. The agreement follows the expiration of the previous license on 30 November 2025. The directors of both Jacobson and JBM, including their independent non-executive directors, consider the terms of the agreement to be fair, reasonable, on normal commercial terms, and in the best interests of the companies and their shareholders. Certain directors abstained from voting on the relevant board resolutions to avoid potential conflicts of interest.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JBM (Healthcare) Ltd. published the original content used to generate this news brief on October 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1606","symbol_name":"中医药概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nNDL4lxyrS:1","article_id":"2578932037","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2578932037","pubTimestamp":1761647591,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"JBM  Ltd. has announced that Europharm and Europharm HK have entered into the 2025 Europharm License Agreement on 28 October 2025. Under this agreement, Europharm will grant a license to Europharm HK to use a portion of the Factory from 1 December 2025 to 27 January 2028, for a monthly license fee of HK$247,000. The agreement follows the expiration of the previous license on 30 November 2025. The directors of both Jacobson and JBM, including their independent non-executive directors, consider the terms of the agreement to be fair, reasonable, on normal commercial terms, and in the best interests of the companies and their shareholders. Certain directors abstained from voting on the relevant board resolutions to avoid potential conflicts of interest.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1606":"中医药概念","BK1191":"制药","02161":"健倍苗苗"},"translate_title":"JBM（医疗保健）签署2025年Europharm许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02161":0.9},"content_text":"JBM (Healthcare) Signs 2025 Europharm License Agreement\n    \n\n        JBM (Healthcare) Ltd. has announced that Europharm and Europharm HK have entered into the 2025 Europharm License Agreement on 28 October 2025. Under this agreement, Europharm will grant a license to Europharm HK to use a portion of the Factory from 1 December 2025 to 27 January 2028, for a monthly license fee of HK$247,000. The agreement follows the expiration of the previous license on 30 November 2025. The directors of both Jacobson and JBM, including their independent non-executive directors, consider the terms of the agreement to be fair, reasonable, on normal commercial terms, and in the best interests of the companies and their shareholders. Certain directors abstained from voting on the relevant board resolutions to avoid potential conflicts of interest.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JBM (Healthcare) Ltd. published the original content used to generate this news brief on October 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2578932037","isCrawlerRequest":true}